What is the appropriate evaluation and management for a 64-year-old man with an absolute eosinophil count of 518 cells/µL (8.1%)?

Mild Eosinophilia - Likely Benign but Requires Targeted Evaluation

For a 64-year-old man with an absolute eosinophil count of 518 cells/µL (8.1%), this represents mild eosinophilia (defined as >500 cells/µL) that warrants a focused diagnostic workup to exclude helminth infection and other secondary causes, but does not require urgent intervention or specialist referral at this level 1.

Initial Risk Stratification

This patient's eosinophil count falls just above the threshold for eosinophilia (>0.5 × 10⁹/L) but well below hypereosinophilia (≥1.5 × 10⁹/L). At this level:

• No immediate concern for end-organ damage - This occurs primarily with persistent hypereosinophilia ≥1.5 × 10⁹/L for >3 months 1
• Allergy is the most common cause in non-endemic settings, but helminth infection must be excluded given the high diagnostic yield (19-80%) in appropriate populations 1
• Malignancy and clonal disorders are extremely unlikely at this mild elevation 2

Essential History Elements

Focus your history on these specific high-yield areas:

• Travel or migration history: Any residence in or travel to helminth-endemic regions (sub-Saharan Africa, Southeast Asia, Latin America) - even decades ago, as some helminths persist 20-25 years 1
• Timing: When did eosinophilia first appear? Any new medications started within 2-8 weeks? 1
• Atopic conditions: Asthma, eczema, allergic rhinitis (most common non-infectious causes) 1
• Gastrointestinal symptoms: Diarrhea, abdominal pain, weight loss
• Respiratory symptoms: Cough, wheezing, dyspnea
• Skin manifestations: Rash, urticaria, pruritus
• Current medications: Many drugs cause eosinophilia 1

Recommended Diagnostic Workup

First-Line Testing

If ANY travel/residence history in endemic regions 1:

1. Concentrated stool microscopy (3 samples on different days)
2. Strongyloides serology - Critical because of hyperinfection risk with immunosuppression 1
3. Schistosoma serology - High diagnostic yield across all travel regions 1
4. Stool PCR if available - Better sensitivity than microscopy 1
5. HIV testing per BHIVA guidelines if indicated 1

Filarial testing (serology only, NOT day/night blood films) - ONLY if travel to/residence in West Africa 1

If No Travel History

• Review medication list thoroughly
• Assess for atopic disease severity
• Consider basic allergy evaluation if clinically indicated

Management Approach

Empirical Treatment Consideration

If travel history is positive but stool microscopy is negative, consider empirical treatment 1:

• Albendazole 400 mg single dose PLUS
• Ivermectin 200 μg/kg single dose
• Critical: Exclude Loa loa before ivermectin if West African travel (risk of severe reactions) 1
• Repeat treatment at 8 weeks to cover schistosomiasis (eggs/immature forms are treatment-resistant) 1

Watch and Wait Approach

For mild eosinophilia <1.5 × 10⁹/L without symptoms or organ involvement, close follow-up with repeat counts is appropriate 3. This patient qualifies for this approach if:

• No travel history to endemic areas
• No concerning symptoms
• Likely atopic/allergic etiology identified

Key Pitfalls to Avoid

1. Don't miss Strongyloides: Standard stool microscopy has lower sensitivity; serology is essential 1
2. Don't give ivermectin without excluding Loa loa in West African travelers 1
3. Don't pursue extensive hematologic workup at this mild elevation - reserve for persistent hypereosinophilia ≥1.5 × 10⁹/L for >3 months after excluding infectious causes 1
4. Don't assume allergy alone if count persists - hypereosinophilia is rarely explained by allergy alone 2

Follow-Up

• Repeat eosinophil count in 4-8 weeks to assess trend
• Refer to hematology only if eosinophilia persists ≥1.5 × 10⁹/L for >3 months after infectious causes excluded/treated 1
• Monitor for symptoms of organ involvement (cardiac, pulmonary, neurologic)